Metabolomics, the study of small molecules within cells, is transforming the biotech industry. Companies like Akero Therapeutics, Holoclara, and MAX BioPharma are leveraging metabolomics to develop innovative treatments for diseases such as metabolic dysfunction-associated steatohepatitis (MASH), allergic and autoimmune disorders, and chronic inflammation. These companies are using metabolomics to identify novel biomarkers, understand disease mechanisms,…
pharmacy on The Soothsayer
Researchers have made a groundbreaking discovery in the field of anti-aging, successfully reversing the aging process in mice by injecting them with an RNA molecule. The treatment targets cellular senescence, a hallmark of aging, and has shown promising results in restoring the mice’s physical and mental abilities. This breakthrough could potentially lead to the development…
Researchers from the Centre for Medical Radiation Physics at the University of Wollongong in Australia have made a significant breakthrough in brain cancer treatment by combining microbeam radiation therapy (MRT) with targeted radiosensitizers. This innovative approach has shown promising results in killing cancer cells while sparing healthy tissues. The study, published in Cancers, demonstrates the…
Researchers at the California Institute of Technology and the University of Southern California have made a groundbreaking discovery in the field of biomedical engineering. They have designed a hydrogel-based, image-guided, bioresorbable acoustic microrobot (BAM) that can deliver targeted doses of cancer-fighting drugs to destroy malignant tumors while sparing healthy bodily tissues. The microrobots use a…
The U.S. Food and Drug Administration (FDA) has approved 50 new molecular entities in 2024, with 24 designated as first-in-class therapies. This trend is expected to continue in 2025, with several first-in-class drugs set to be approved. These innovative treatments offer new approaches to challenging diseases, including schizophrenia, metabolic-associated steatohepatitis, and rare genetic disorders. Forecast…
A recent report by Clarivate highlights several blockbuster drugs poised to revolutionize the biotech industry. These treatments, expected to generate over $1 billion in sales, include CagriSema for type 2 diabetes, Awiqli for long-acting insulin, Cobenfy for schizophrenia, and several others. As these drugs make their way to market, they are expected to transform the…
The world of medicine is on the cusp of a revolution with the development of new weight-loss drugs and breakthroughs in various fields. Eli Lilly’s oral pill orforglipron and Amgen’s maritide are set to change the game in treating obesity and diabetes. Meanwhile, researchers are exploring the potential of GLP-1 agonists to treat other illnesses,…
A breakthrough in psychiatric medicine has been announced with the approval of KarXT, a schizophrenia drug that targets muscarinic receptors. This innovative approach has sparked excitement among researchers, but the road to success is long and challenging. Several similar drugs are in development, but the success of these medicines is not guaranteed. The recent failure…
A looming patent cliff threatens to disrupt the pharmaceutical industry, with over $200 billion in annual revenue at risk through 2030. However, this presents a significant opportunity for biosimilar developers to capitalize on the transition to more affordable treatments. Several companies, including Alvotech, Biocon Biologics, Celltrion, Formycon, and Samsung Bioepis, are already making strides in…
The biotech industry is witnessing a surge in the development of bispecific antibodies, a type of targeted therapy that can deliver two-in-one treatments to patients with cancer and other diseases. Several companies, including Adaptin Bio, Akeso, AP Biosciences, Candid Therapeutics, Summit Therapeutics, and Zenas BioPharma, are working on various bispecific antibody candidates, some of which…
